

**S1 Table.** Third-line chemotherapy regimen according to the prior second-line chemotherapy

Second-line chemotherapy	Fluoropyrimidine -oxaliplatin doublets	Fluoropyrimidine monotherapy	p-value
<b>Patient receiving third-line chemotherapy after progression</b>	38/77 (49.4%)	14/34 (41.2%)	0.43
<b>Third-line regimen</b>			
FOLFOX	1	1	
XELOX	-	11	
Nal-IRI+5-FU/LV	4	2	
5-FU/LV	2	-	
S-1	25	-	
Capecitabine	3	-	
UFT	1	-	
Investigational drugs	2	-	

FOLFOX, folinic acid, fluorouracil and oxaliplatin; XELOX, capecitabine plus oxaliplatin; Nal-IRI, liposomal irinotecan; 5-FU, fluorouracil; LV, leucovorin; S-1, tegafur/gimeracil/oteracil; UFT, uracil-tegafur.